Biosimilar Newsletter Archive

1. 06.23.22 -- EMA Accepts Sandoz's Proposed High Concentration Formulation of Humira Biosimilar 6/23/2022
   06/23/22 Biosimilar Development Newsletter
2. 06.16.22 -- Key Considerations In Early-Stage Biopharma Financing 6/16/2022
   06/16/22 Biosimilar Development Newsletter
3. 06.13.22 -- Patient-Centric Drug Delivery Focused On Quality And Regulatory Standards 6/13/2022

   06/13/22 Biosimilar Development Newsletter

4. 06.13.22 -- Mechanistic Chromatography Modeling For Smarter Process Development 6/13/2022

   06/13/22 Biosimilar Development Newsletter

5. 06.10.22 -- De-Risking Combination Product Development For Biosimilars 6/10/2022

   06/10/22 Biosimilar Development Newsletter

6. 06.09.22 -- New Episodes for You: Live Biologics & The Microbiome, Inside CAR-T Therapy for Ovarian Cancer and more. 6/9/2022
   06/09/22 Biosimilar Development Newsletter
7. 06.09.22 -- Sandoz Announces New Global Act4Biosimilars Initiative 6/9/2022
   06/09/22 Biosimilar Development Newsletter
8. 06.02.22 -- The Single-Use Bioprocessing Bottleneck: Looking Ahead 6/2/2022
   06/02/22 Biosimilar Development Newsletter
9. 05.26.22 -- A Better Path For CMO Relationships 5/26/2022
   05/26/22 Biosimilar Development Newsletter
10. 05.25.22 -- Key Considerations To Drive Bioprocess Innovation 5/25/2022

    05/25/22 Biosimilar Development Newsletter